Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
Andrei GafitaHui WangRobert TauberCalogero D'AlessandriaWolfgang A WeberMatthias EiberPublished in: European journal of nuclear medicine and molecular imaging (2019)